{"content":[{"text":"September 16, 2008","bbox":{"left":0.730822,"top":0.134487,"width":0.148397,"height":0.017395999999999995}},{"text":"Contents of Stock Acquisition Rights \n (Stock Option Scheme as Stock-Linked Compensation Plan)","bbox":{"left":0.241524,"top":0.180655,"width":0.517055,"height":0.04111699999999999}},{"text":"Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, \n hereinafter called “the Company,”) today announced that it decided the contents of the stock \n acquisition rights to the Directors and Corporate executive of the Company, resolved at the meeting of \n the Board of Directors held on August 29, 2008.","bbox":{"left":0.120964,"top":0.248501,"width":0.7583120000000001,"height":0.06015200000000001}},{"text":"Particular","bbox":{"left":0.464199,"top":0.334012,"width":0.07178800000000002,"height":0.017396000000000023}},{"text":"1.","bbox":{"left":0.120966,"top":0.363157,"width":0.013853999999999991,"height":0.017396000000000023}},{"text":"Name of stock acquisition rights to be offered:","bbox":{"left":0.166296,"top":0.363157,"width":0.344059,"height":0.017396000000000023}},{"text":"Astellas Pharma Inc. Stock Acquisition Rights issued in September 2008","bbox":{"left":0.176408,"top":0.391803,"width":0.5377310000000001,"height":0.017396000000000023}},{"text":"2.","bbox":{"left":0.120966,"top":0.421732,"width":0.013863,"height":0.017396000000000023}},{"text":"Total number of stock acquisition rights to be offered:","bbox":{"left":0.166305,"top":0.421732,"width":0.39891599999999994,"height":0.017396000000000023}},{"text":"727 units (100 shares per stock acquisition right)","bbox":{"left":0.176408,"top":0.450308,"width":0.36104899999999995,"height":0.017396000000000023}},{"text":"3.","bbox":{"left":0.120966,"top":0.479453,"width":0.013853999999999991,"height":0.017396000000000023}},{"text":"Type and number of shares to be issued upon exercise of stock acquisition rights:","bbox":{"left":0.166296,"top":0.479453,"width":0.599944,"height":0.017396000000000023}},{"text":"Shares of common stock of the Company 72,700 shares","bbox":{"left":0.176408,"top":0.508099,"width":0.412065,"height":0.017395999999999967}},{"text":"4.","bbox":{"left":0.120966,"top":0.537244,"width":0.013865000000000002,"height":0.017395999999999967}},{"text":"The amount to be paid for stock acquisition rights to be offered:","bbox":{"left":0.168625,"top":0.537244,"width":0.472475,"height":0.017395999999999967}},{"text":"¥ 398,000 per stock acquisition right (option value: ¥ 3,980 per share)","bbox":{"left":0.177919,"top":0.567315,"width":0.5167680000000001,"height":0.017395999999999967}},{"text":"(Note) \n Besides above information, please refer to “Allotment of Stock Acquisition Rights (Stock Option \n Scheme as Stock-Linked Compensation Plan)” issued on August 29, 2008.","bbox":{"left":0.120966,"top":0.610213,"width":0.7583099999999999,"height":0.056942999999999966}},{"text":"#####","bbox":{"left":0.476902,"top":0.695722,"width":0.04621700000000001,"height":0.017395999999999967}},{"text":"Contacts for inquiries or additional information \n Astellas Pharma Inc. \n Corporate Communications \n Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 \n http://www.astellas.com","bbox":{"left":0.251201,"top":0.742824,"width":0.4240630000000001,"height":0.09399899999999994}}],"images_bbox":[{"left":0.071167,"top":0.952688,"width":0.220218,"height":0.018856},{"left":-0.007459,"top":0.004133,"width":1.00047,"height":0.111306}],"images_bbox_not_text_overlap":[{"left":0.071167,"top":0.952688,"width":0.220218,"height":0.018856},{"left":-0.007459,"top":0.004133,"width":1.00047,"height":0.111306}]}